All In Biotech

Drug Trial Radar · NCT07039669

Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Multi-Centered, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial, to Evaluate the Efficacy and Safety of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease

Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 594 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

594

Planned (sponsor's estimate)

Start

Jul 16, 2025

Primary completion

Sep 2028

Study completion Nov 2028

Sponsor

Sponsor type
Industry
First posted
Jun 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.

Conditions

  • Pulmonary Disease, Chronic Obstructive (COPD)

Interventions

  • 611Drug

    611 subcutaneous (SC) injection

  • PlaceboDrug

    placebo Q2W, subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized rate of moderate or severe COPD ExacerbationsTime frame: Baseline to Week 52

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Shenzhen People's Hospital

    Shenzhen, Guangdong, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

  • ZheJiang Provincial People's Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.